Shares of tiny biotech iBio Inc. IBIO, +9.30% surged another 19% in premarket trade Thursday, on continued strong hopes for its partnership with a Chinese company on a plant-based vaccine to treat the coronavirus. In the latest news on iBio, which has seen its stock gain 767% in the year so far, the company on Monday canceled plans for a reverse stock split, which was needed before the recent rally to avoid a delisting. That news led to some profit taking this week, that has the stock showing a week-to-date decline of about 12%. The stock has mostly rallied since it announced the partnership last month with Beijing CC-Pharming Ltd. The company is aiming to use its FastPharming facility, which was set up to create rapid delivery of medical countermeasures to treat a pandemic. The partnership aims to leverage CC-Pharming's work on Middle East respiratory syndrome, or MERS, another coronavirus, and iBio's manufacturing processes in plant-based expression systems. New York-based iBio specializes in plant-based biologics manufacturing.